1. Home
  2. DLTR vs RPRX Comparison

DLTR vs RPRX Comparison

Compare DLTR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dollar Tree Inc.

DLTR

Dollar Tree Inc.

N/A

Current Price

$121.13

Market Cap

23.2B

ML Signal

N/A

RPRX

Royalty Pharma plc

N/A

Current Price

$58.78

Market Cap

25.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLTR
RPRX
Founded
1986
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.2B
25.9B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
DLTR
RPRX
Price
$121.13
$58.78
Analyst Decision
Hold
Strong Buy
Analyst Count
18
5
Target Price
$123.35
$51.40
AVG Volume (30 Days)
3.4M
2.8M
Earning Date
06-03-2026
05-06-2026
Dividend Yield
N/A
1.90%
EPS Growth
144.33
N/A
EPS
1.76
0.67
Revenue
$19,411,800,000.00
$2,378,193,000.00
Revenue This Year
$8.48
$38.63
Revenue Next Year
$5.90
$4.73
P/E Ratio
$66.85
$88.09
Revenue Growth
10.43
5.06
52 Week Low
$84.71
$34.63
52 Week High
$142.40
$59.44

Technical Indicators

Market Signals
Indicator
DLTR
RPRX
Relative Strength Index (RSI) 50.23 59.32
Support Level $117.54 $54.95
Resistance Level $132.87 $58.84
Average True Range (ATR) 3.93 1.28
MACD -1.29 0.07
Stochastic Oscillator 21.95 77.36

Price Performance

Historical Comparison
DLTR
RPRX

About DLTR Dollar Tree Inc.

Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2025, Dollar Tree generated over $19 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: